Moderna’s new mRNA flu vaccine, mFlusiva, has received approval from the Food and Drug Administration (FDA) specifically for use in adults aged 50 and older. This groundbreaking vaccine has been found to be approximately 27% more effective than standard flu shots, according to the company. The announcement was made in a statement by Moderna on August 5, indicating a significant advancement in flu prevention, particularly for the senior population.
:max_bytes(150000):strip_icc():format(jpeg)/moderna-080626-dd4b26136f95416da183c80a47cea462.jpg)
Stéphane Bancel, the CEO of Moderna, remarked on the importance of this milestone, highlighting that mFlusiva represents the company’s fourth approved product in the United States and marks the first mRNA-based influenza vaccine to be authorised. He emphasised the ongoing challenges posed by influenza and showcased mFlusiva as a critical addition to the options available for America’s older adults. Bancel attributed the success of the vaccine to the collective effort of clinical trial participants, researchers, and various teams at Moderna.
According to research from Moderna, this new flu vaccine boasts an efficacy rate of about 83%, significantly higher than the effectiveness rates of traditional flu vaccines, which generally range between 22% and 56%. This increase in efficacy is particularly timely, as the Centers for Disease Control and Prevention (CDC) reported approximately 45,000 flu-related deaths in the United States during the year 2025. With infection rates on the rise, a more effective vaccine for older adults could prove vital in protecting this vulnerable demographic.
At its core, Moderna’s mFlusiva vaccine leverages mRNA technology, which utilises messenger ribonucleic acid to prompt an immune response from the body. Unlike conventional vaccines that typically introduce inactivated or weakened virus particles, the mRNA approach instructs cells to replicate a component of the virus, subsequently generating a stronger immune response. This method was previously successful with the COVID-19 vaccine, and its application to influenza is being closely watched by public health officials and the scientific community.
The path to mFlusiva’s approval was not without its challenges. Under the Trump administration, the FDA had delayed the approval of several mRNA vaccines beyond the COVID-19 landscape. This cautionary approach stemmed from concerns regarding the safety and testing of mRNA technology. Reports indicate that the U.S. Department of Health and Human Services (HHS) even cancelled a substantial contract for Moderna’s development of a bird flu vaccine, reflecting a broader hesitation within government circles about further investment in mRNA technology at that time.
Andrew Nixon, an HHS spokesperson, noted back then that the agency prioritised safety and integrity, asserting that mRNA technology still needed extensive testing before it could be widely deployed. These sentiments indicated a significant level of distrust from certain governmental entities regarding the rollout of mRNA-based products.
Further complicating matters, HHS Secretary Robert F. Kennedy Jr. has been a vocal critic of vaccines generally, advocating against the use of mRNA technology shortly after the COVID-19 vaccine became available. This stance has raised concerns regarding public acceptance of mRNA flu vaccines, even as scientific evidence begins to favour their efficacy.
Despite these hurdles, Moderna’s advancements signal a pivotal shift in influenza vaccination strategies. As seasonal flu continues to pose a substantial public health risk, particularly among seniors, mFlusiva offers hope for a more robust defence against the virus. The successful deployment of this vaccine could not only reduce mortality rates but also alleviate the strain on healthcare systems during flu season.
As healthcare providers prepare for the upcoming flu season, the introduction of mFlusiva may transform the way influenza is treated and prevented among seniors. This development underscores the importance of continued innovation in vaccine technology, particularly as infectious diseases remain a major public health concern.